Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schold, S. C.
Right arrow Articles by Falletta, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schold, S. C., Jr
Right arrow Articles by Falletta, J. M.
NEUROLOGY 1984;34:615
© 1984 American Academy of Neurology

Treatment of patients with recurrent primary brain tumors with AZQ

S. Clifford Schold, Jr, MD, Henry S. Friedman, MD, Thorir D. Bjornsson, MD and John M. Falletta, MD

From the Department of Medicine (Neurology) and Department of' Pathology (Neuropathology) (Dr. Schold); Department (11 Pediatrics (Hematology-Oncdogy) (Drs. Friedman and Fallettal; and Department of Pharmacology (Clinical Pharmacology) (Dr. Bjornsson). Duke University Medical Center. Durham, NC. Dr. Friedman is a recipient of a Brain Tumor Research Association Fellowship in memory of Bryce Davis.

We have evaluated the efficacy of intravenous 2,5-diaziridinyl-3,6-biscarboethoxyamino-l,4-benzoquinone (diaziquone or AZQ, NSC-182986) in the treatment of recurrent primary anaplastic brain tumors. Three of 16 evaluable patients (18.8%) showed clinical and radiographic improvement that permitted discontinuation of corticosteroids, 4 patients (25%) showed either clinical or radiographic improvement and were considered partial responders, and 9 patients (56.2%) showed no effects after two courses of AZQ. The treatment was well tolerated, and hematologic toxicity was mild. Pharmacokinetic studies indicated rapid decay of the parent compound from plasma using two different infusion schedules. These results compare favorably with those obtained using the nitrosoureas or procarbazine as single agents.

Address correspondence and reprint requests to Dr. Schold. Box 2905. Duke University Medical Center, Durham. NC 27710.

Accepted for publication September 9, 1983.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1984 by AAN Enterprises, Inc.